These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 4728690)

  • 1. Effect of polyriboinosinic-polyribocytidylic acid and antibody on infection of immunosuppressed mice with vaccinia virus.
    Worthington M; Baron S
    J Infect Dis; 1973 Sep; 128(3):308-11. PubMed ID: 4728690
    [No Abstract]   [Full Text] [Related]  

  • 2. The immune response to infection with vaccinia virus in mice. I. Infection and the production of antibody neutralizing cell-associated and cell-free virus.
    Hutt LM
    J Hyg (Lond); 1975 Jun; 74(3):301-14. PubMed ID: 168248
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical treatment of cutaneous vaccinia virus infections in immunosuppressed hairless mice with selected antiviral substances.
    Smee DF; Bailey KW; Wong MH; Tarbet EB
    Antivir Chem Chemother; 2011 May; 21(5):201-8. PubMed ID: 21566266
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. II. Effect of multiple doses of polyriboinosinic-polyribocytidylic acid on viral pathogenesis.
    Stringfellow DA; Overall JC; Glasgow LA
    J Infect Dis; 1974 Nov; 130(5):481-8. PubMed ID: 4371529
    [No Abstract]   [Full Text] [Related]  

  • 5. [The effect of Trichinella spiralis on the susceptibility and antibody production to vaccinia virus].
    Chimishkian KL; Ovumian GSh
    Vopr Virusol; 1975; (4):438-41. PubMed ID: 1216835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antibodies to the A27 protein of vaccinia virus neutralize and protect against infection but represent a minor component of Dryvax vaccine--induced immunity.
    He Y; Manischewitz J; Meseda CA; Merchlinsky M; Vassell RA; Sirota L; Berkower I; Golding H; Weiss CD
    J Infect Dis; 2007 Oct; 196(7):1026-32. PubMed ID: 17763325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Effect of phosphonoacetic acid on experimental vaccinia infection].
    Andzhaparide OG; Bektemirov TA; Burgasova MP; Chekunova EV
    Vopr Virusol; 1978; (1):56-9. PubMed ID: 645058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid detection of anti-Vaccinia virus neutralizing antibodies.
    Kramski M; Drozd A; Lichtfuss GF; Dabrowski PW; Ellerbrok H
    Virol J; 2011 Mar; 8():139. PubMed ID: 21439060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy of vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model.
    McCausland MM; Benhnia MR; Crickard L; Laudenslager J; Granger SW; Tahara T; Kubo R; Koriazova L; Kato S; Crotty S
    Antivir Ther; 2010; 15(4):661-75. PubMed ID: 20587859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combinations of polyclonal or monoclonal antibodies to proteins of the outer membranes of the two infectious forms of vaccinia virus protect mice against a lethal respiratory challenge.
    Lustig S; Fogg C; Whitbeck JC; Eisenberg RJ; Cohen GH; Moss B
    J Virol; 2005 Nov; 79(21):13454-62. PubMed ID: 16227266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon inducers in therapy of infection with encephalomyocarditis virus in mice. I. Effect of single doses of polyriboinosinic-polyribocytidylic acid and tilorone hydrochloride on viral pathogenesis.
    Stringfellow DA; Overall JC; Glasgow LA
    J Infect Dis; 1974 Nov; 130(5):470-80. PubMed ID: 4371528
    [No Abstract]   [Full Text] [Related]  

  • 12. [A new experimental model of vaccinia infection].
    Rytik PG; Boĭko VI; Votiakov VI; Pinchuk SI; Gudkov VG
    Vopr Virusol; 1976; (4):465-8. PubMed ID: 1007222
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization assay using a modified vaccinia virus Ankara vector expressing the green fluorescent protein is a high-throughput method to monitor the humoral immune response against vaccinia virus.
    Cosma A; Bühler S; Nagaraj R; Staib C; Hammarin AL; Wahren B; Goebel FD; Erfle V; Sutter G
    Clin Diagn Lab Immunol; 2004 Mar; 11(2):406-10. PubMed ID: 15013995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed hypersensitivity in vaccinia-infected mice. II. Resistance of peritoneal macrophages against vaccinia infection.
    Ueda S; Nozima T
    Acta Virol; 1973 Jan; 17(1):41-9. PubMed ID: 4405395
    [No Abstract]   [Full Text] [Related]  

  • 15. The effect of cyclophosphamide on intracerebral vaccinia virus infection in Balb/C mice.
    Ginsberg AH; Johnson KP
    Exp Mol Pathol; 1977 Dec; 27(3):285-94. PubMed ID: 923746
    [No Abstract]   [Full Text] [Related]  

  • 16. Antibody studies in natural bovine cowpox.
    Baxby D; Osborne AD
    J Hyg (Lond); 1979 Dec; 83(3):425-8. PubMed ID: 512354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of vaccinia antigen and antibody by counterelectrophoresis.
    Kyriakidou A; Kourea-Kremastinou T; Papaevangelou G; Vassiliadis P
    Pathol Microbiol (Basel); 1973; 39(2):126-34. PubMed ID: 4196961
    [No Abstract]   [Full Text] [Related]  

  • 18. Studies on poxvirus infections in irradiated animals.
    Werner GT; Jentzsch U; Metzger E; Simon J
    Arch Virol; 1980; 64(3):247-56. PubMed ID: 6250514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical treatment of vaccinia virus infection with an interferon inducer in rabbits.
    Levy HB; Lvovsky E
    J Infect Dis; 1978 Jan; 137(1):78-81. PubMed ID: 624854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice.
    Davies DH; McCausland MM; Valdez C; Huynh D; Hernandez JE; Mu Y; Hirst S; Villarreal L; Felgner PL; Crotty S
    J Virol; 2005 Sep; 79(18):11724-33. PubMed ID: 16140750
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.